Steris price target raised to $225 from $220 at Piper Sandler

Piper Sandler raised the firm’s price target on Steris to $225 from $220 and keeps a Neutral rating on the shares. The analyst says “extraordinarily strong” healthcare equipment deliveries drove the company’s fiscal Q4 financials well above consensus. However, the firm believes the shares are fully valued at current levels.